These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 39334169)

  • 1. Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
    Joers V; Murray BC; McLaughlin C; Oliver D; Staley HE; Coronado J; Achat-Mendes C; Golshani S; Kelly SD; Goodson M; Lee D; Manfredsson FP; Moore Ii BM; Tansey MG
    J Neuroinflammation; 2024 Sep; 21(1):240. PubMed ID: 39334169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
    Joers V; Murray BC; McLaughlin C; Oliver D; Staley H; Coronado J; Achat-Mendes C; Golshani S; Kelly SD; Goodson M; Lee D; Manfredsson FP; Moore BM; Tansey MG
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
    J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.
    Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M
    J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
    Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
    Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPER activation is effective in protecting against inflammation-induced nigral dopaminergic loss and motor function impairment.
    Mendes-Oliveira J; Lopes Campos F; Videira RA; Baltazar G
    Brain Behav Immun; 2017 Aug; 64():296-307. PubMed ID: 28450223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition.
    Stoll AC; Kemp CJ; Patterson JR; Kubik M; Kuhn N; Benskey M; Duffy MF; Luk KC; Sortwell CE
    J Neuroinflammation; 2024 Apr; 21(1):108. PubMed ID: 38664840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroinflammation and protein pathology in Parkinson's disease dementia.
    Kouli A; Camacho M; Allinson K; Williams-Gray CH
    Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.
    Kelly R; Bemelmans AP; Joséphine C; Brouillet E; McKernan DP; Dowd E
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
    Chung YC; Shin WH; Baek JY; Cho EJ; Baik HH; Kim SR; Won SY; Jin BK
    Exp Mol Med; 2016 Jan; 48(1):e205. PubMed ID: 27534533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies.
    Fleming SM; Davis A; Simons E
    Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
    Concannon RM; Okine BN; Finn DP; Dowd E
    Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JWH133 attenuates behavior deficits and iron accumulation in 6-OHDA-induced Parkinson's disease model rats.
    Liu M; Pan D; Wang M; Deng H; Ma Z
    J Neurophysiol; 2024 Sep; 132(3):733-743. PubMed ID: 39015077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
    FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.